QMS Medical

Why is QMS Medical Allied Services Ltd falling/rising?

As of 18-Jul, QMS Medical Allied Services Ltd's stock price is Rs 109.81, reflecting a slight decline, but it has shown strong year-to-date and one-year returns of 22.56% and 32.30%, respectively. Despite attractive valuation metrics, a 36% decrease in profits and reduced investor participation may be contributing to the recent price drop.

As of 18-Jul, QMS Medical Allied Services Ltd is experiencing a slight decline in its stock price, currently at Rs 109.81, which reflects a change of -0.43 (-0.39%). Despite this recent drop, the stock has shown strong performance over various periods, including a year-to-date increase of 22.56% and a one-year return of 32.30%, significantly outperforming the broader market, which has seen a decline of 6.87% over the same timeframe.<BR><BR>The stock's recent performance indicates it is trading higher than its moving averages across multiple time frames, suggesting a generally positive trend. Additionally, it is close to its 52-week high, being only 3.82% away from Rs 114. However, there are signs of falling investor participation, as evidenced by a 19.71% decrease in delivery volume compared to the 5-day average, which may contribute to the current price decline.<BR><BR>While the stock has attractive valuation metrics, such as a return on capital employed (ROCE) of 13.3 and a fair trading value compared to peers, it is important to note that its profits have decreased by 36% over the past year. This decline in profitability, coupled with reduced investor engagement, may be influencing the stock's current downward movement despite its overall strong performance in the market.

Which are the latest news on QMS Medical?

Should I buy, sell or hold QMS Medical Allied Services Ltd?

What does QMS Medical do?

QMS Medical Allied Services Ltd markets and distributes a variety of medical products and equipment in the healthcare sector. As of March 2026, it reported net sales of 44 Cr and a net profit of 2 Cr, with a market cap of INR 181 Cr.

Overview: <BR>QMS Medical Allied Services Ltd is engaged in the marketing, trading, and distribution of a wide range of medical products, instruments, equipment, and devices within the healthcare services industry, categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated as 'QMS Medical Allied Services Private Limited' in 2017 and changed its status to a public limited company on October 22, 2020. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 44 Cr (Quarterly Results - Mar 2026) <BR>- Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>- Market Cap: INR 181 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 17.00 <BR>- Industry P/E: 92 <BR>- Dividend Yield: 0.54% <BR>- Debt-Equity: 0.58 <BR>- Return on Equity: 9.76% <BR>- Price to Book: 1.73 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is QMS Medical?

As of 10th June, QMS Medical Allied Services Ltd has a market capitalization of 181.00 Cr, with recent net sales of 172.88 Cr and a net profit of 10.17 Cr.

As of 10th June, QMS Medical Allied Services Ltd has a market capitalization of 181.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, QMS Medical reported Net Sales of 172.88 Cr and a Net Profit of 10.17 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 89.71 Cr and Total Assets of 189.79 Cr.

Who are in the management team of QMS Medical?

The management team of QMS Medical includes Mahesh Makhija (Chairperson & Managing Director), Diti Makhija (Non-Executive Director), Guddi Makhija (Whole-time Director), Gautam Khanna (Non-Executive Independent Director), Raju Bhatia (Non-Executive Independent Director), and Deepali Malpani (Company Secretary & Compliance Officer).

The management team of QMS Medical includes the following individuals:<BR><BR>1. **Mahesh Makhija** - Chairperson & Managing Director<BR>2. **Diti Makhija** - Non-Executive & Non-Independent Director<BR>3. **Guddi Makhija** - Whole-time Director<BR>4. **Gautam Khanna** - Non-Executive & Independent Director<BR>5. **Raju Bhatia** - Non-Executive & Independent Director<BR>6. **Deepali Malpani** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the QMS Medical?

QMS Medical's peers include Take Solutions, Nureca, Bilcare, Jeevan Scienti., Prevest Denpro, Hemant Surgical, Star Imaging, and Aspira Pathlab. QMS Medical has average management risk and growth, with a 1-year return of 7.75%, compared to Take Solutions' highest return of 226.63% and Nureca's lowest at -22.60%.

Peers: The peers of QMS Medical are Take Solutions, Nureca, Bilcare, Jeevan Scienti., Prevest Denpro, Hemant Surgical, Star Imaging, and Aspira Pathlab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prevest Denpro and Star Imaging, while Average management risk is found at QMS Medical and Hemant Surgical. Below Average management risk is noted for Take Solutions, Nureca, Bilcare, Jeevan Scienti., Aspira Pathlab, and the rest. Growth is rated as Good for Hemant Surgical and as Average for QMS Medical and Jeevan Scienti., while Below Average growth is seen in Take Solutions, Nureca, Bilcare, and the rest. Capital Structure is rated as Excellent for Prevest Denpro, Good for Nureca and Hemant Surgical, Average for QMS Medical and Aspira Pathlab, and Below Average for Take Solutions, Bilcare, Jeevan Scienti., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Take Solutions at 226.63%, while Nureca has the lowest at -22.60%. QMS Medical's 1-year return is 7.75%, which is significantly lower than Take Solutions but higher than Nureca. Additionally, peers such as Nureca and Bilcare have negative six-month returns.

Are QMS Medical Allied Services Ltd latest results good or bad?

QMS Medical Allied Services Ltd's latest results are concerning, showing a 48.50% decline in net profit year-on-year and a drop in operating margin to 12.97%. Despite a slight recovery in net sales, the overall financial health is deteriorating due to rising costs and interest expenses, leading to negative investor sentiment.

The latest results for QMS Medical Allied Services Ltd indicate a challenging financial performance. In Q4 FY26, the company reported a consolidated net profit of ₹1.72 crores, which represents a significant decline of 48.50% year-on-year and a decrease of 28.33% quarter-on-quarter. This sharp drop in profitability is concerning, especially given that the operating margin fell to 12.97%, the lowest in eight quarters, down from 19.49% in the same quarter last year.<BR><BR>While net sales showed a slight recovery with a 19.22% increase compared to the previous quarter, they still experienced a marginal decline of 0.36% year-on-year. This suggests that despite a sequential improvement in revenue, the overall financial health of the company is deteriorating, primarily due to rising operational costs and significant interest expenses.<BR><BR>The return on equity has also dropped to 10.20%, which is below industry standards, raising further concerns about the company's efficiency and profitability. The stock has reacted negatively to these results, declining by 0.57% post-announcement, reflecting investor disappointment.<BR><BR>Overall, the results can be characterized as bad, highlighting serious issues with profitability, margin compression, and rising debt levels, which pose significant risks to the company's future performance.

How has been the historical performance of QMS Medical?

QMS Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 156.01 Cr and profit after tax increasing to 13.70 Cr. The company also saw improvements in operating profit and cash flow from operating activities, despite a decline in cash flow from investing activities.

Answer:<BR>The historical performance of QMS Medical shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, QMS Medical reported net sales of 156.01 Cr, an increase from 122.13 Cr in the previous year. Total operating income also rose to 156.01 Cr from 122.13 Cr, while total expenditure increased to 130.60 Cr from 103.78 Cr. The operating profit (PBDIT) excluding other income improved to 25.41 Cr from 18.35 Cr, leading to an overall operating profit of 27.13 Cr compared to 18.81 Cr in the prior year. Profit before tax saw a rise to 18.66 Cr from 12.24 Cr, and profit after tax increased to 13.70 Cr from 9.00 Cr. The earnings per share (EPS) grew to 6.7 from 5.04. On the balance sheet, total assets increased to 189.79 Cr from 135.32 Cr, with total liabilities also rising to 189.79 Cr from 135.32 Cr. Cash flow from operating activities significantly improved to 20.00 Cr from 1.00 Cr, while cash flow from investing activities worsened to -45.00 Cr from -2.00 Cr. Overall, QMS Medical demonstrated a positive trend in revenue and profitability, alongside a notable increase in total assets and liabilities.

Is QMS Medical overvalued or undervalued?

As of August 14, 2025, QMS Medical is considered an attractive investment due to its undervalued status with a PE ratio of 12.50, an EV to EBITDA ratio of 8.20, and a PEG ratio of 0.63, especially when compared to higher valuations of peers like Poly Medicure and Blue Jet Health, despite a year-to-date stock decline of 33.85% against the Sensex's gain of 4.17%.

As of 14 August 2025, QMS Medical's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 12.50, an EV to EBITDA ratio of 8.20, and a PEG ratio of 0.63, suggesting that it is trading at a discount relative to its earnings growth potential.<BR><BR>In comparison to its peers, QMS Medical stands out as more reasonably priced. For example, Poly Medicure has a PE ratio of 53.86, while Blue Jet Health is at 38.33, both of which are significantly higher than QMS Medical's valuation. Additionally, the company's return on capital employed (ROCE) is 13.06%, which further supports its attractiveness in the healthcare services industry. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 33.85% compared to the Sensex's gain of 4.17%, the underlying valuation metrics suggest that QMS Medical presents a compelling investment opportunity.

Who are the top shareholders of the QMS Medical?

The top shareholders of QMS Medical include Mahesh Pahalraj Makhija with 71.98%, individual investors with 22.95%, and a foreign institutional investor holding 0.01%. There are no mutual funds invested, and no pledged promoter holdings indicate strong promoter commitment.

The top shareholders of QMS Medical primarily include the promoters, with Mahesh Pahalraj Makhija holding the largest share at 71.98%. Additionally, individual investors collectively hold 22.95% of the shares. There is one foreign institutional investor (FII) that holds a small portion of 0.01%, but there are no mutual funds currently invested in the company. There are no pledged promoter holdings, indicating a strong commitment from the promoters.

What is the technical trend for QMS Medical?

As of May 16, 2025, QMS Medical's technical trend is mildly bearish, with bearish daily moving averages and mixed signals from MACD and Dow Theory, despite a mildly bullish weekly MACD.

As of 16 May 2025, the technical trend for QMS Medical has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages are bearish. The Bollinger Bands and KST both show bearish signals on the weekly timeframe. The Dow Theory suggests a mildly bullish trend on the weekly, but the overall indicators lean towards a bearish sentiment. The OBV is mildly bearish on the weekly and monthly. Overall, the current technical stance is mildly bearish, with key indicators being the bearish moving averages and the mixed signals from MACD and Dow Theory.

When is the next results date for QMS Medical?

No Upcoming Board Meetings

Has QMS Medical declared dividend?

QMS Medical Allied Services Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating financial challenges despite the dividend announcement.

QMS Medical Allied Services Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.58%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.57%, the dividend return was 0%, resulting in a total return of -22.57%.<BR><BR>Over the past year, the price return was -11.98%, the dividend return was 0.47%, leading to a total return of -11.51%.<BR><BR>For the 2-year period, the price return was -28.34%, the dividend return was 0.65%, which resulted in a total return of -27.69%.<BR><BR>In the 3-year period, there was no price return, no dividend return, and the total return remained at 0.0%.<BR><BR>For the 4-year period, there was also no price return, no dividend return, and the total return stayed at 0.0%.<BR><BR>In the 5-year period, there was no price return, no dividend return, and the total return was 0.0%.<BR><BR>Overall, while QMS Medical has declared a dividend, the total returns over various periods indicate negative performance, particularly in the short and medium term, suggesting challenges in the company's financial performance despite the dividend announcement.